Biotech M&A Market Sees Revival as Capital Markets Reopen

Barclays' Emily Field, Head of U.S. Biopharma Equity Research, recently shared her insights on the biotech M&A market's revival after a long freeze. According to Field, the slowdown in mergers and acquisitions (M&A) was largely due to uncertainty during the Trump administration regarding drug pricing and broader policy. However, with 2026 marking a turning point, Field believes capital markets are reopening for many biotech companies.

Field points out that large-cap pharma buyers such as AbbVie and Merck have committed to more deals despite facing patent cliffs in the coming years. The analyst highlighted the success of Moderna's personalized mRNA cancer vaccine, which showed a 49% reduction in risk of recurrence or death with the vaccine plus KEYTRUDA compared to KEYTRUDA alone. This has led to significant market gains for both companies.

Revolution Medicines' RAS(ON) inhibitor developer also made headlines with its Phase 3 results in previously treated metastatic pancreatic cancer, demonstrating a median overall survival of 13.2 months versus 6.7 months for chemotherapy. With shares up 162.98% year to date and a $45 billion market cap, Revolution Medicines remains on the industry's oncology M&A radar.